A Study of MK0359 in Patients With Chronic Asthma (0359-013)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Asthma

Treatments

Drug: MK0359

Study type

Interventional

Funder types

Industry

Identifiers

2007_575

MK0359-013

0359-013

Details and patient eligibility

About

A study to test the effect of MK0359 in lessening the symptoms of asthma as compared to placebo.

Enrollment

56 patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

You are between the ages of 18 and 45
You have had a history for at least a year of COPD symptoms
Your current asthma treatment is limited to short-acting beta-agonists(such as albuterol)
You have a history of smoking one pack of cigarettes per day for 7 years
You will not be away from home for more than 5 days during the study

Exclusion criteria

You are unwilling to limit your alcohol use to less than 5 drinks per week
You have been in a research study with an investigational drug or vaccine in the last 4 weeks
You have donated blood in the last 4 weeks
You have been hospitalized or had major surgery in the last 4 weeks
You have been treated in the emergency room within the last 4 weeks or hospitalized within the last 3 months for your asthma
You have a history of heart problems in the last 6 months
You have a history of stomach problems
You are unwilling to avoid grapefruit juice throughout the study